Aspirin, cardiovascular events, and major bleeding in older adults: extended follow-up of the ASPREE trial: @ESC_Journals
🥸Aspirin for primary prevention for older pts = MACE!
👇👇👇👇
🥸1️⃣ ASPREE was a large randomized trial designed to evaluate whether daily low-dose aspirin prevents cardiovascular events in initially healthy older adults.
🥸2️⃣ ASPREE enrolled 19,114 community-dwelling adults ≥70 (≥65 for US minorities), free of prior cardiovascular disease, dementia, or disability. Participants were randomized to 100 mg aspirin or placebo and followed in-trial (median 4.7 yrs) and post-trial (median 4.3 yrs).
Acute coronary syndromes: mechanisms, challenges, and new opportunities: @ESC_Journals
🥸Very nice review -
😱Many research questions
👇👇👇
🥸1️⃣ Acute coronary syndromes remain a leading cause of global mortality, with one out of three deaths attributed to atherosclerosis and its acute or chronic complications.
🥸2️⃣ Most ACS events are caused by coronary plaque rupture or plaque erosion, but other mechanisms include calcific nodules, embolism, spontaneous coronary artery dissection (SCAD), coronary spasm, and microvascular dysfunction.
Mitral valve replacement or repair and long-term risk of infective endocarditis: a Danish nationwide study: @ESC_Journals
🥸Nice study - mitral valve replacement and infective endocarditis during follow-up
👇👇👇
🥸1️⃣ This Danish nationwide cohort study examined the 10-year risk of first-time infective endocarditis (IE) in patients after mitral valve (MV) replacement or repair, compared to those at moderate risk of IE, using high-quality registry data from 2000–2020.
🥸2️⃣ The study included 1220 patients who underwent isolated MV replacement, 3239 who underwent MV repair, and 209,517 categorized as moderate risk of IE (such as those with CIEDs, congenital valve anomalies, HCM, rheumatic or degenerative valve disease).
Alcohol Use and Cardiovascular Disease: A Scientific Statement From the American Heart Association: @CircAHA
🥸 Great work from @AHAScience
😱 No level of alcohol is truly “safe”: Summary
👇👇👇
🥸1️⃣ Alcohol use and cardiovascular disease (CVD) have a complicated and often debated relationship; this AHA statement reviews decades of research on coronary artery disease (CAD), stroke, heart failure (HF), arrhythmias, and cardiomyopathy.
🥸2️⃣ Most evidence linking alcohol and CVD is observational, with strong risks for bias and confounding; randomized trials are rare, and definitive answers are lacking.
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity: @NEJM
🥸 SURMOUNT-5 Trial: Wow!
😱 Summary
👇👇👇
🥸 1️⃣ SURMOUNT-5 directly compares tirzepatide and semaglutide for obesity in adults without diabetes. First head-to-head randomized trial of these two GLP-1–based agents. Published @NEJM, May 2025.
[DOI: 10.1056/NEJMoa2416394]
🥸 2️⃣ 751 adults with BMI ≥30 or ≥27 + 1 comorbidity (HTN, dyslipidemia, OSA, or CVD) were randomized to tirzepatide (10 or 15 mg) or semaglutide (1.7 or 2.4 mg) once weekly for 72 weeks. No participants had type 2 diabetes.
Healthy ageing in older adults with cardiovascular disease: @ESC_Journals
🥸 So proud of Nathalie, Jon & @KritiKalra092 for their hard work
😱 With my friend @MichaelGNanna in published in the European Heart Journal
🥸What is healthy aging? How do we achieve it?
👇👇👇
🥸 1️⃣ Healthy ageing in cardiovascular disease matters because by 2050, adults 65+ will represent over 20% of the U.S. and nearly 30% of Europe's population, dramatically shifting healthcare needs.
🥸 2️⃣ Cardiovascular disease already leads all causes of death globally, and as populations age, CVD-related disability and healthcare costs will keep rising.